Skip to main content

The BioPharma Dive Outlook on 2021

M&A appears to be ticking higher after a slow 2020, while a series of setbacks has renewed questions around gene therapy. Several key clinical trial readouts also loom. Here's what to watch in biotech and pharma this year.

included in this trendline
  • Key trends in biotech dealmaking to watch in 2021
  • The clinical trials and FDA approval decisions to watch in the first half of the year
  • Top questions facing gene therapy and the FDA this year
Note: Trendlines are a premium product, available to subscribers of our free newsletters. Access this Trendline by signing up for the BioPharma Dive newsletter or enter your information if you're already subscribed.
Produced by our team of award-winning journalists, these Outlooks can help businesses navigate the uncertain road ahead in 2021.
Davide Savenije Editor-in-Chief at Industry Dive.